Atlas Trials

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

Clinical trial NCT06742281 · COMPLETED

Trial details

NCT number
NCT06742281
Sponsor
CyanVac LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2024-12-05
Primary completion
2026-06-15
Enrollment
432

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.